Received Jun 15, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 3CA5T | — |
Possible administration with sterile diluent; Possible administration with sterile diluent; This non-serious case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a patient who received RSVPreF3 adjuvanted (Arexvy) suspension for injection (batch number 3CA5T with expiry date 27-FEB-2027) for prophylaxis. On 08-JUN-2026, the patient received Arexvy. On 08-JUN-2026, an unknown time after receiving Arexvy, the patient experienced wrong solution used in drug reconstitution (Verbatim: Possible administration with sterile diluent) and inappropriate dose of vaccine administered (Verbatim: Possible administration with sterile diluent). The outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 08-JUN-2026 A reporter requested data about the possibility of having had administered Arexvy with sterile water diluent instead of the adjuvant in an unknow patient, with the administration taking place in the last week.